Peptide Inhalation Solutions: Bioavailability & Stability Analysis
Title: Peptide Inhalation Solutions: Bioavailability & Stability Analysis Abstract: Peptide inhalation solutions offer enhanced bioavailability via pulmonary delivery, bypassing gastrointestinal degradation. However, stability challenges persist due to enzymatic cleavage and aggregation. Current market trends show a CAGR of 8.5% (2023–2030), driven by respiratory and metabolic applications. Leading brands (e.g., A, B) differ in excipient composition and particle size (1–5 μm), impacting lung deposition. Regulatory certifications (GMP, ISO) are critical for quality assurance. Comparative data indicate that lyophilized formulations improve shelf-life by 40% versus liquid forms. Selection criteria prioritize purity (>98%) and validated stability studies. Logistics require cold-chain maintenance (2–8°C) to preserve bioactivity. Industry growth is fueled by rising demand for non-invasive peptide therapies.